insulin resistance/Dm2 microbiota
Conditions
Interventions
donor fecestransplantaton (allogenic) or fecal transplantation with own feces
(autologous)
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: patients: -treatment naive metabolic syndrome/insulin resistant subjects -surinamese asian or caucasian ethnicity - male/postmenopauzal female - age 40-65 years donors: -healthy (no medication use) - enriched gutmicrobiota desulfovibrio levels
Exclusion criteria
Exclusion criteria: -unable to provide written informed consent- - antibiotics / PPI-antacids use in the last 3 months - nicotine/alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes are changes in periperhal insulin sensitivity(as determined by stable isotope (6-6-D2) based hyperinsulinemic clamp for calculation of endogenous hepatic glucose prodution). Also, changes in glucose excursions as detrmined by FreeStyle Libre sensors in relation to changes in (oral , small intestinal and fecal) gut microbiota diversity and composition at baseline and after 6 weeks of FMT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are changes in post fructose (13c stable isotope) challenge enrichment of metabolites including alcohol in plasma, 24h urine , 24h feces as well as changes in small intestinal fructose receptor expression and fructose oxidation in exhaled air at these timepoints.Other secondary outcomes comprise changes in MRI imaging of hepatic fat content measured before and after FMT as well as changes in fecal and plasma SCFA and bileacid levels. | — |
Countries
Netherlands
Outcome results
None listed